Synergy Pharmaceuticals: Should You Buy the Dip Ahead of FDA Approval?

Shares of biopharma Synergy Pharmaceuticals (NASDAQ:SGYP) are now almost half the price one month ago following a controversial equity offering. With prices so low, does this stock now make a compelling opportunity for the savvy investor?

Story Continues

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts